# US 2008/0306005 A1 · Treatment of bone disorders with skeletal anabolic drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306005 A1
- Document ID: US20080306005A1
- Status: Published application
- Kind: A1
- Application number: 12/110,118
- Filed: 2008-04-25
- Published: 2008-12-11
- Earliest claimed: 2002-01-10
- Assignees: Osteotrophin, LLC
- Inventors: Andrew F. Stewart
- Web page: https://patentgrep.com/patent/US20080306005A1

## CPC

- A61K 38/29: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of metabolic bone disorders that are both effective and have an increased safety.

## Claims

### Claim at position 1

-21. (canceled)

### Claim 22

A method of increasing bone mass in a human patient in need thereof, said method comprising administering intermittently to said patient parathyroid hormone-related protein (PTHrP) at a dosage of at least 600 μg/day for a period of at least one month, wherein the bone mass density of said patient increases at a rate of at least 1% per month.

### Claim 23 (depends on 22)

The method of claim 22, wherein the bone mass density of said patient increases at a rate of at least 1.5% per month over a period of at least three months.

### Claim 24 (depends on 23)

The method of claim 23, wherein said human patient is afflicted with, or at risk of, primary or secondary osteoporosis.

### Claim 25 (depends on 23)

The method of claim 23, wherein said human patient is afflicted with, or at risk of, a metabolic bone disorder selected from the group consisting of: osteomalacia, renal osteodystrophy, and other types of skeletal disorders with associated bone loss.

### Claim 26 (depends on 23)

The method of claim 23, wherein PTHrP is administered subcutaneously.

### Claim 27

A method of treating a human patient afflicted with osteoporosis, said method comprising administering intermittently parathyroid hormone-related protein (PTHrP) to said patient at a dosage of at least about 600 μg/day for a period of about 1 to about 36 months, wherein the bone mass density of said patient increases at a rate of at least 1% per month.

### Claim 28 (depends on 27)

The method of claim 27, wherein the bone mass density of said patient increases at a rate of at least 1.5% per month over a period of at least three months.

### Claim 29 (depends on 28)

The method of claim 28, wherein said PTHrP is administered subcutaneously.

### Claim 30 (depends on 28)

The method of claim 28, wherein said PTHrP is administered by the route of administration selected from the group consisting of: oral, intravenous, intraperitoneal, intramuscular, buccal, rectal, vaginal, intranasal, and aerosol administration.

### Claim 31 (depends on 28)

The method of claim 28, wherein said PTHrP is administered until the bone mass density of said patient is restored.

### Claim 32 (depends on 23)

The method of claim 23, wherein the period of administration is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, 21, 24, 30, and 36 months.

### Claim 33 (depends on 22)

The method of claim 22, wherein the bone mass density of the patient increases at a rate selected from the group consisting of at least 1.1% per month, at least 1.2% per month, at least 1.3% per month, at least 1.4% per month, at least 1.5% per month, and at least 1.6% per month over a period of at least three months.

### Claim 34 (depends on 23)

The method of claim 23, wherein the method results in a reduction in fractures selected from the group consisting of at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, and at least 95%.

### Claim 35 (depends on 23)

The method of claim 23, wherein the intermittent administration is selected from the group consisting of once daily, once every two days, once every three days, once weekly, twice weekly biweekly, twice monthly, monthly, and a combination thereof.

### Claim 36 (depends on 23)

The method of claim 23, further comprising co-administering, either simultaneously or sequentially with PTHrP, a bone resorption inhibiting agent.

### Claim 37 (depends on 36)

The method of claim 36, wherein the bone resorption-inhibiting agent is selected from the group consisting of a bisphosphonate, estrogen, a selective estrogen receptor modulator, a selective androgen receptor modulator, calcitonin, a vitamin D analog, a calcium salt, alendronate, risedronate, etidronate, pamidronate, tiludronate, zoledronic acid, raloxifene, tamoxifene, droloxifene, toremifene, idoxifene, levonneloxifene, and conjugated estrogens.

### Claim 38 (depends on 23)

The method of claim 23, wherein the PTHrP has an amino acid sequence as shown in SEQ ID NO:2.

### Claim 39 (depends on 23)

The method of claim 23, wherein the PTHrP is naturally-occurring PTHrP, synthetic PTHrP, or recombinant PTHrP.

### Claim 40 (depends on 23)

The method of claim 23, wherein the PTHrP has an amino acid sequence which differs from that shown in SEQ ID NO:2 by one or more conservative amino acid substitutions.

### Claim 41 (depends on 23)

The method of claim 23, wherein the PTHrP has an amino acid sequence which is at least 90% homologous to the amino acid sequence of SEQ ID NO:2.

### Claim 42 (depends on 23)

The method of claim 23, wherein the PTHrP has an amino acid sequence which is at least 95% homologous to the amino acid sequence of SEQ ID NO:2.

### Claim 43 (depends on 22)

The method of claim 22, wherein the PTHrP is human PTHrP.

### Claim 44

A method of increasing bone mass in a human patient in need thereof, said method comprising administering intermittently to said patient parathyroid hormone-related protein (PTHrP) at a dosage of at least 600 μg/day for a period of at least one month, wherein the bone mass density of said patient increases at a rate of at least 1% per month over a period of at least three months.

### Claim 45

A method of treating a human patient afflicted with osteoporosis, said method comprising administering intermittently parathyroid hormone-related protein (PTHrP) to said patient at a dosage of at least about 600 μg/day for a period of about 1 to about 36 months, wherein the bone mass density of said patient increases at a rate of at least 1% per month over a period of at least three months.
